ASCO Gastrointestinal | Conference

STORM: Adjuvant Sorafenib Had No Effect on HCC Recurrence
June 10, 2014

Treatment with sorafenib after curative resection or ablation of hepatocellular carcinoma did not improve recurrence-free survival compared with placebo, according to the results of the phase III STORM trial.

Cediranib Improves Response Rate, Not PFS in Biliary Tract Cancer
June 10, 2014

The addition of cediranib to treatment with cisplatin/gemcitabine did not improve progression-free survival in patients with advanced biliary tract cancer, according to the results of the phase II ABC-03 trial.

Ruxolitinib May Boost Survival in Pancreatic Cancer
June 06, 2014

The JAK inhibitor ruxolitinib may improve overall survival in patients with metastatic pancreatic cancer characterized by an elevated CRP, a well-established marker of inflammation.